Re: Farmas USA
The wild card here may be held by the Obama administration. The wave of tax inversions that hit last year spurred Treasury to come up with some new tax rules that made it harder to pull off a deal like this. Faced with the loss of Pfizer, the administration may be willing to go one more big step forward on that front. And don't forget the current controversy over drug pricing and the election year ahead. Candidates are likely to step in here as well, and Pfizer isn't likely to get much sympathy from either party for a tax dodge like this.
UPDATED: Analysts review the pros and pitfalls involved in a Pfizer/Allergan megamerger